Heart and Blood Diseases

Symptoms and General Pathology

All Conditions

Rare Diseases

Myocardial Infarction

ST Elevation Myocardial Infarction

Infarction

Necrosis

Ischemia

Tissue Adhesions

Coronary Artery Disease

Myocardial Ischemia

Heart Diseases

Vascular Diseases

Acute Graft Versus Host Disease

Hypoglycemic Agents

All Drugs and Chemicals

Fibrinolytic Agents

Vasodilator Agents

Respiratory System Agents

Reproductive Control Agents

Insulin

Insulin, Globin Zinc

Plasminogen

Plasminogen Inactivators

Nitric Oxide

Dinoprost

Dinoprost tromethamine

Plasminogen Activator Inhibitor 1

In this group study, a condition of Hyperinsulinemia/Euglycaemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.

In this group study, a condition of Hyperinsulinemia/Hyperglycemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.

In this group study, a condition of Hypoinsulinemia/Hyperglycemia will be held trough clamp study, during witch FMD will be measured before and after ischemia/reperfusion injury.

Andrei C Sposito, PhD, MD

Riobaldo R Cintra, MD

Thiago Quinaglia, PhD, MD

Valeria N Figueiredo, PhD

The objective of this study is to investigative the influence of different levels of glycaemia or insulinemia in vascular endothelium in ischemia/reperfusion lesion after myocardial infarction

The study will include patients consecutively admitted with acute myocardial infarction at State University of Campinas Hospital. Participants will be evaluated during hospitalization and, after they fulfill the inclusion criteria and sign an informed consent, it will be collected a brief medical history and recorded results from glycated hemoglobin (HbA1c), glycaemia, total cholesterol (TC), triglycerides (TG), HDL cholesterol (HDL-C), C-reactive protein (CRP), urea (U), creatinine (Cr), markers of myocardial necrosis (troponin T and CK-MB), Hemoglobin, Red blood cell, Leucocytes, Na, K, Ca and Mg.

In the first week after infarction, from admission until the realization of the clamps experiments (the medical procedure where blood glucose and insulin levels will be controlled), all medications prescribed, medical history and examination will be recorded, as well as follow-up during hospitalization.

At the day of the clamp, between 144 and 168 hours after infarction, volunteers will be randomized to one of the three situations with different glycemic and insulinemic conditions, i.e., a) high insulinemia and low glycaemia, b) high insulinemia and high glycaemia and c) low insulinemia and high glycaemia. During these experiments, endothelial vasomotor function will be recorded in four periods: i) before initiation of the procedure, ii) after 1h of the beginning, iii) 30 minutes after the second procedure and iv) 15 minutes after the simulation of ischemia/reperfusion lesion. In each time point, the investigators will collect plasma to dose inflammatory, oxidative stress and vascular activation markers.

Hospital care of subjects

The patients included in this survey will be treated according to actual guidelines. Briefly, will be enrolled patients who underwent primary angioplasty within 6 hours after symptoms onset, were introduced antiplatelet and anticoagulation therapy at the correct dose, respectively Acetylsalicylic Acid (ASA) 200 mg and Clopidogrel 300 mg, and enoxaparin 30 mg. In patients without contraindication, it will be administered in the first 24 hours beta-blockers and ACEi in those with ejection fraction (EF) \<0.4, previous MI or prior heart failure. Upon admission, if there is no contraindication, simvastatin 40 mg/day will be administered. As a maintenance dose, the investigators will administer ASA 100 mg, clopidogrel 75 mg, enoxaparin 1 mg/kg twice daily, simvastatin 40 mg, propranolol 40 mg or metoprolol 50 mg (beta-blockers available at the hospital) and captopril 25 mg (most used ACEi). Patients will be treated preferably in the Coronary Unit (CU). Researchers may suggest the physician responsible for the patient care to prescribe the above medications, as well as question why the drugs listed in the guidelines are not being used. The reasons and specific contraindications will be recorded.

The researchers are not directly responsible for the treatment of individuals, which does not absolve them of responsibility for any adverse effects related to the experiments. Also, the investigators emphasize that the study did not interfere with the flow of patients during hospitalization, i.e., will not influence the discharge of patients.

Randomization to one of the three clamps

As observed, the investigators will evaluate endothelial reactivity by FMD. On the day of the clamp, after fasting, they will be exposed to one of three situations: (i) hyperglycemia / hypoinsulinemia, (ii) euglycaemia / hyperinsulinemia and (iii) hyperglycemia / hyperinsulinemia.

The clamps will simulate the possible attenuation or increase in endothelial reactivity promoted by the independent variables during ischemia/reperfusion (I/R) injury. In total, the test will consist of realization of a basal FMD-1 (during 15 minutes), clamps (variable length, usually 60 minutes), FMD-2 (15 min) after the clamp, rest time (30 min), ischemia/reperfusion (20 min) injury, rest time (15 min) and FMD-3 (15 min). Throughout the experiment, blood glucose and insulin will be controlled and maintained at levels such as designed previously for each clamp situation. In all subjects, plasma samples will be collected before the start of the clamp (during FMD-1), at the end of the measurement of the second FMD during the clamp, prior to the I/R injury and 15 minutes after the end of the same test (during FMD-3). In these samples will be dosed insulin, glucose, C-peptide, C-reactive protein, tumor necrosis factor-α (TNF-α), nitric oxide, intercellular adhesion molecule-1 (ICAM-1), plasminogen activator inhibition-1 (PAI-1), isoprostane and interleucin-1 (IL-1).

In one group, the euglycemic/hyperinsulinemic consists of a situation in which insulin levels are above physiological levels and blood glucose levels maintained at approximately 100 mg/dL. Euglycemic/hyperinsulinemic clamp is similar to the way the hyperinsulinemic/hyperglycemic clamp is performed, although reaching a glucose level of approximately 150 mg/dL. During the clamp with hypoinsulinemia/hyperglycemia, will be infused a somatostatin analogue (octreotide) for 30 minutes (t = 0 min) and subsequently infusion of 20% glucose to achieve glycaemia of approximately 150 mg/dL (t = 30 min).

Ischemia/Reperfusion Injury The I/R injury is intended to simulate at the brachial artery a condition similar to coronary lesion resulting from infarction after reperfusion. This experiment will be performed 30 min after the measurement of FMD-2, positioning a pneumatic cuff at level of brachial artery, inflating it to 200 mmHg for 15 minutes. After this period of ischemia, the cuff is deflated and is subsequently performed the brachial reactivity test. This ischemia period is safe, as shown in other studies.

Statistical analysis Data will presented as mean ± standard deviation (SD) when normally distributed or median and interquartile range (IQR) for non-normal data. Categorical variables will be compared by chi-square. Continuous variables with normal distribution will be compared using analysis of covariance (ANCOVA) adjusted for age, gender, size of MI estimated by peak CK-MB and estimated by heart rate variability sympathetic activity. Prerequisites for the ANCOVA models (linearity, normality and equal variance) will be checked using histograms, normal probability plots and residual dispersion. Non-normal continuous variables may be transformed logarithmically. If, after the transformation, they persist not normal, will be analyzed by the Kruskal-Wallis test. Analysis will be performed using the SPSS 22 application, Mac version.

The Influence of Glycaemia and Insulinemia on Vasomotor Endothelial Function After Myocardial Infarction

Influence of Glycaemia and Insulinemia on Vasomotor Endothelial Function After Ischemia/Reperfusion Lesion on Patients in Acute Phase of ST Segment Elevation Myocardial Infarction (STEMI)

Compare the effects of euglycemic/hyperinsulinemic, hyperglycemic/hypoinsulinemic and hyperglycemic/hyperinsulinemic on endothelial reactivity, measured by flow mediated dilation, after ischemia/reperfusion injury assessed at brachial artery.

Compare the effects of euglycemic/hyperinsulinemic, hyperglycemic/hypoinsulinemic and hyperglycemic/hyperinsulinemic on nitric oxide generation before and after ischemia/reperfusion injury assessed at brachial artery.

Compare the effects of euglycemic/hyperinsulinemic, hyperglycemic/hypoinsulinemic and hyperglycemic/hyperinsulinemic on markers of inflammatory activity (CRP, TNF alpha, IL-1 beta and IL-10) in after ischemia/reperfusion injury assessed at brachial artery.

Compare the effects of euglycemic/hyperinsulinemic, hyperglycemic/hypoinsulinemic and hyperglycemic/hyperinsulinemic on markers of endothelial activation (ICAM-1, VCAM-1, PAI-1) in after ischemia/reperfusion injury assessed at brachial artery.

Compare the effects of euglycemic/hyperinsulinemic, hyperglycemic/hypoinsulinemic and hyperglycemic/hyperinsulinemic on markers of oxidative stress (nitrotyrosine and 8-isoprostane) before and after ischemia/reperfusion injury assessed at brachial artery

University of Campinas, Brazil

Assistent Professor, Cardiology Division

Neoplasms

Skin and Connective Tissue Diseases

Substance Related Disorders

Wounds and Injuries

Breast Neoplasms

Cardiotoxicity

Drug-Related Side Effects and Adverse Reactions

Chemically-Induced Disorders

Radiation Injuries

Chronic Graft Versus Host Disease

Antineoplastic Agents

Antirheumatic Agents

Cyclophosphamide

Doxorubicin

Liposomal doxorubicin

Superoxide Dismutase

Immunosuppressive Agents

Immunologic Factors

Antineoplastic Agents, Alkylating

Alkylating Agents

The patients will be assessed before and after chemotherapy treatment.

Body weight, height and waist circumference

Physical Characteristics

Muscular Sympathetic Nervous Activity

Cardiac Function

Heart rate

Blood pressure

Serum and Plasma will be extracted by centrifugation. Endothelial microparticles by flow cytometry Interleukin-6 and tumor necrosis factor α by ELISA, High-sensitive reactive serum C-reactive protein by immunoturbidimetric assay, NT- ProBNP According to Central Laboratory, Hospital das Clinicas, HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo. Endothelin-1 by immunoenzymatic method Nitric oxide by gas chemiluminescence Lipoperoxidation by fluorimetry Carbonyl by spectrophotometer, and Superoxide Dismutase (SOD) by colorimetry.

Blood Assessments

Muscle blood flow

Endothelium-dependent vascular function

Vascular intima-media thickness

Physical Capacity

Four session of intravenous (in bolus) infusion of doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 with an interval of 21 days between sessions.

Anthracycline & Cyclophosphamide treatment scheme

Raphaela VR Groehs, PhD

Ursula Urias, PhD

Carlos Eduardo Negrao, PHD

Carlos E Negrao, PhD

The present study aims to investigate the chronic effect of treatment with doxorubicin and cyclophosphamide on neurovascular control and blood pressure in women undergoing adjuvant treatment for breast cancer.

The development of new drugs and different adjuvant therapeutic regimens, based on the combination of anthracycline (A) and cyclophosphamide (C), have contributed greatly to improve survival rate in breast cancer patients. Despite the clinical benefits of this therapy, AC treatment can cause cardiovascular acute and chronic changes. In a recent investigation, we observed that an acute AC chemotherapy session increases sympathetic nervous activity and blood pressure in patients with breast cancer.

The present study aims to investigate the chronic effects of AC regimen on sympathetic nervous activity, peripheral vasoconstriction, endothelial microparticles and blood pressure, in women with breast cancer.

Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses

Chronic Effect of Doxorubicin and Cyclophosphamide on Neurovascular Control and Blood Pressure in Women in Adjuvant Treatment for Breast Neoplasia

Change in muscular sympathetic nerve activity measured by microneurography

Change in muscle blood flow measured by venous oclusion plethysmography

Change in blood pressure measured by finometer

Change in physical capacity measured by cardiopulmonary exercise test

Change in cardiac function measured by echocardiography

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
The Influence of Glycaemia and Insulinemia on Vasomotor Endothelial Function After Myocardial Infarction	NCT02250989	Myocardial Infa...		40 Years - 70 Years	University of Campinas, Brazil
Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses	NCT04568161	Cardiotoxicity Cardiovascular ... Neurovascular D... Endothelial Dis... Breast Cancer	Physical Charac... Muscular Sympat... Cardiac Functio... Heart rate Blood pressure Blood Assessmen... Muscle blood fl... Endothelium-dep... Vascular intima... Physical Capaci... Anthracycline &...	45 Years - 60 Years	University of Sao Paulo General Hospital
Effect of Anthracyclines and Cyclophosphamide on Cardiovascular Responses	NCT04568161	Cardiotoxicity Cardiovascular ... Neurovascular D... Endothelial Dis... Breast Cancer	Physical Charac... Muscular Sympat... Cardiac Functio... Heart rate Blood pressure Blood Assessmen... Muscle blood fl... Endothelium-dep... Vascular intima... Physical Capaci... Anthracycline &...	45 Years - 60 Years	University of Sao Paulo General Hospital
The Influence of Glycaemia and Insulinemia on Vasomotor Endothelial Function After Myocardial Infarction	NCT02250989	Myocardial Infa...		40 Years - 70 Years	University of Campinas, Brazil

Spots Global Cancer Trial Database for endothelial disfunction